RAM
CYTK icon

Readystate Asset Management’s Cytokinetics CYTK Stock Holding History

Readystate Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122,711
Closed -$7.8M – 830
2025
Q4 		$7.8M Sell
122,711
-19,771
-14% -$1.23M 0.32% 67
2025
Q3 		$7.83M Buy
142,482
+10,264
+8% +$423K 0.33% 73
2025
Q2 		$4.37M Sell
132,218
-15,951
-11% -$555K 0.13% 111
2025
Q1 		$5.95M Buy
148,169
+87,194
+143% +$4.01M 0.2% 83
2024
Q4 		$2.87M Sell
60,975
-92,889
-60% -$4.82M 0.09% 236
2024
Q3 		$8.12M Sell
153,864
-240,311
-61% -$13.4M 0.15% 261
2024
Q2 		$21.4M Sell
394,175
-71,323
-15% -$4.31M 0.69% 29
2024
Q1 		$32.6M Buy
465,498
+409,198
+727% +$31.6M 0.46% 17
2023
Q4 		$4.7M Buy
+56,300
New +$2.04M 0.16% 137

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Readystate Asset Management's CYTK Position: Q1 2026 in Review

Readystate Asset Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 122,711 shares — an estimated $7.8M sold.

Readystate Asset Management first reported a position in CYTK in Q4 2023 and held it in 9 quarters. The position peaked at $32.6M in Q1 2024. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Readystate Asset Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Readystate Asset Management sold 122,711 Cytokinetics shares in Q1 2026, an estimated $7.8M.
  • Readystate Asset Management first reported a position in Cytokinetics in Q4 2023 and held it in 9 quarters.
  • Readystate Asset Management's Cytokinetics position peaked at $32.6M in Q1 2024.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.